Published in Toxins (Basel) on May 19, 2015
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
Multiple sclerosis. N Engl J Med (2000) 12.69
Charybdotoxin, a protein inhibitor of single Ca2+-activated K+ channels from mammalian skeletal muscle. Nature (1985) 4.95
Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis? Nature (1984) 4.70
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol (1994) 4.24
Apamin blocks certain neurotransmitter-induced increases in potassium permeability. Nature (1979) 3.93
Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther (2006) 3.61
International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev (2005) 3.50
A regenerative approach to the treatment of multiple sclerosis. Nature (2013) 3.42
The functional network of ion channels in T lymphocytes. Immunol Rev (2009) 3.21
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A (2006) 3.13
K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci (2004) 3.12
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest (2003) 3.02
K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature (1984) 2.89
Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem (2000) 2.85
Mutant potassium channels with altered binding of charybdotoxin, a pore-blocking peptide inhibitor. Science (1989) 2.75
A unified nomenclature for short-chain peptides isolated from scorpion venoms: alpha-KTx molecular subfamilies. Trends Pharmacol Sci (1999) 2.71
Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A (2001) 2.63
Hanatoxin modifies the gating of a voltage-dependent K+ channel through multiple binding sites. Neuron (1997) 2.62
How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol (2006) 2.38
Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity (2008) 2.23
Mapping the receptor site for charybdotoxin, a pore-blocking potassium channel inhibitor. Neuron (1990) 2.14
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol (2005) 2.08
Apamin as a selective blocker of the calcium-dependent potassium channel in neuroblastoma cells: voltage-clamp and biochemical characterization of the toxin receptor. Proc Natl Acad Sci U S A (1982) 2.01
Purification and characterization of three inhibitors of voltage-dependent K+ channels from Leiurus quinquestriatus var. hebraeus venom. Biochemistry (1994) 1.97
A novel high-affinity inhibitor for inward-rectifier K+ channels. Biochemistry (1998) 1.95
Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. J Biol Chem (1993) 1.94
Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol (2001) 1.85
Ion channels and transporters in lymphocyte function and immunity. Nat Rev Immunol (2012) 1.74
Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol (1990) 1.70
Topology of the pore-region of a K+ channel revealed by the NMR-derived structures of scorpion toxins. Neuron (1995) 1.70
Tarantula toxins interacting with voltage sensors in potassium channels. Toxicon (2006) 1.69
Ca(2+)-activated K+ channels in human leukemic T cells. J Gen Physiol (1992) 1.66
K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol (2004) 1.65
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol (2005) 1.63
Potassium channel distribution, clustering, and function in remyelinating rat axons. J Neurosci (1998) 1.62
Critical appraisal of animal models of multiple sclerosis. Mult Scler (2011) 1.61
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon (2011) 1.59
K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev (2008) 1.52
Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease. J Biol Chem (2008) 1.46
Diversity of folds in animal toxins acting on ion channels. Biochem J (2004) 1.43
Potassium channels, memory T cells, and multiple sclerosis. Neuroscientist (2005) 1.32
Structure of a pore-blocking toxin in complex with a eukaryotic voltage-dependent K(+) channel. Elife (2013) 1.31
Association of Kv1.5 and Kv1.3 contributes to the major voltage-dependent K+ channel in macrophages. J Biol Chem (2006) 1.20
Selective blockage of voltage-dependent K+ channels by a novel scorpion toxin. Nature (1982) 1.17
Subunit composition of brain voltage-gated potassium channels determined by hongotoxin-1, a novel peptide derived from Centruroides limbatus venom. J Biol Chem (1998) 1.15
Intracellular Ca2+ oscillations and membrane potential fluctuations in intact human T lymphocytes: role of K+ channels in Ca2+ signaling. Cell Calcium (1995) 1.13
The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney Int (2014) 1.11
K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem J (2005) 1.11
A new arthritis therapy with oxidative burst inducers. PLoS Med (2006) 1.09
Modulation of Kv channel expression and function by TCR and costimulatory signals during peripheral CD4(+) lymphocyte differentiation. J Exp Med (2002) 1.07
Therapeutic potential of neuronal two-pore domain potassium-channel modulators. Curr Opin Investig Drugs (2007) 1.04
Targeting effector memory T-cells with Kv1.3 blockers. Curr Opin Drug Discov Devel (2007) 1.03
Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol (2010) 1.03
Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3. Biochemistry (2002) 1.02
Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels. Immunol Lett (2010) 1.02
Analysis of potassium channel functions in mammalian axons by gene knockouts. J Neurocytol (2000) 1.01
The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model. J Invest Dermatol (2010) 0.99
Gambierol, a toxin produced by the dinoflagellate Gambierdiscus toxicus, is a potent blocker of voltage-gated potassium channels. Toxicon (2008) 0.97
Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins. J Biol Chem (2004) 0.97
Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells. Mol Pharmacol (2012) 0.96
Virus demyelination. J Neurovirol (2003) 0.95
Selective inhibition of CCR7(-) effector memory T cell activation by a novel peptide targeting Kv1.3 channel in a rat experimental autoimmune encephalomyelitis model. J Biol Chem (2012) 0.93
The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis. Immunobiology (2012) 0.87
Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J (2014) 0.84
Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes. Mol Pharmacol (2004) 0.84
Scorpion venom and multiple sclerosis. Lancet (1983) 0.83
A novel conotoxin inhibiting vertebrate voltage-sensitive potassium channels. Toxicon (2003) 0.81
Use of Kv1.3 blockers for inflammatory skin conditions. Curr Med Chem (2010) 0.80
Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model. J Autoimmun (2014) 0.79
ImKTx88, a novel selective Kv1.3 channel blocker derived from the scorpion Isometrus maculates. Toxicon (2010) 0.78
BF9, the first functionally characterized snake toxin peptide with Kunitz-type protease and potassium channel inhibiting properties. J Biochem Mol Toxicol (2013) 0.78